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Evaluation of the gastrointestinal findings of nodulocystic acne
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Background/aim: Systemic isotretinoin treatment is an effective treatment modality for nodulocystic acne, the clinical use of which
has been associated with reports of adverse events. We conducted a prospective study with the aim of determining the possible
gastrointestinal and laboratory findings of nodulocystic acne patients during systemic isotretinoin treatment.
Materials and methods: Seventy patients with nodulocystic acne completed the study. During the monthly follow-up visits, liver
function tests and lipid profiles of the patients were evaluated and gastrointestinal system complaints were examined.
Results: We recorded a significant elevation in liver function tests and lipid profiles of the patients, the most prominent elevation being
in plasma triglyceride concentrations. We observed that nausea, dyspepsia, abdominal pain, and diarrhea were the rare gastrointestinal
symptoms encountered during systemic isotretinoin therapy. Constipation and anorectal bleeding were relatively more common
symptoms and there seemed to be a relation between these two symptoms.
Conclusion: Our study is the first to analyze the gastrointestinal findings of patients during systemic isotretinoin treatment.
Dermatologists and gastroenterologists must keep in mind that, as well as known laboratory findings like hypertriglyceridemia and
elevated liver function tests, systemic isotretinoin therapy may also cause significant clinical gastrointestinal findings.
Key words: Acne vulgaris, isotretinoin, adverse effects

1. Introduction
Acne is a chronic inflammatory disease of the pilosebaceous
unit resulting from androgen-induced increased sebum
production, altered keratinization, inflammation, and
bacterial colonization of hair follicles on the face, neck,
chest, and back by Propionibacterium acnes (1). It is a
common disease of adolescence and young adulthood.
Targeting of the major pathogenetic factors, depending
on clinical type and severity, represents the most effective
approach to treat acne (2). Systemic isotretinoin as a
monotherapeutic agent strongly affects all four major
pathogenetic factors and it is the most effective medication
resulting in clinical cure in around 85% of cases (1,2).
Isotretinoin is usually reserved for severe nodulocystic
scarring acne or acne resistant to other therapies (1).
The clinical use of oral isotretinoin has been associated
with reports of adverse events with various implications
for the patient. The most common adverse reactions
* Correspondence: t_duru@hotmail.com
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associated with oral isotretinoin are the mucocutaneous
effects (3). Cheilitis is the dominant gastrointestinal
adverse reaction and makes the gastrointestinal system the
body system with the highest frequency of adverse events
(3). Nausea, vomiting, gastric ulcers, abdominal pain, and
inflammatory bowel disease have previously been reported
in the literature (4).
We conducted a prospective study with the aim of
determining the possible gastrointestinal and laboratory
findings of nodulocystic acne patients during systemic
isotretinoin treatment.
2. Materials and methods
Seventy patients with nodulocystic acne who had been
admitted to our outpatient dermatology clinic completed
the study over a period of 2 years. Our institutional review
board approved the project, and informed consent was
appropriately obtained from each participant.
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The nodulocystic acne patients for whom systemic
isotretinoin treatment was planned and whose basal
complete blood count, biochemistry, and lipid profiles
were within normal limits were included in the study.
Female patients were also evaluated for human chorionic
gonadotropin (β-hCG) levels during the basal laboratory
investigation. Patients who were younger than 18 years
old and patients with a history of hyperlipidemia, diabetes
mellitus, hepatitis, pancreatitis, or inflammatory bowel
disease were excluded from the study. The systemic
isotretinoin treatment was continued for 6–8 months for
each patient with an initiation dose of 0.5 mg kg–1 day–1
and a cumulative dose of 150 mg kg–1.
During the monthly follow-up visits liver function
tests and lipid profiles of the patients were evaluated
and gastrointestinal system complaints including
nausea, vomiting, abdominal pain, dyspepsia, diarrhea,
constipation, and bloody stool were examined. If the
patient had a significant complaint or if there was an
abnormality in the laboratory values, the patient was sent
to consult with the gastroenterology department.
2.1. Statistics
Descriptive statistics are presented as frequency,
percentage, and median (min–max) values. Categorical
data (sex, age, nausea, vomiting, dyspepsia, abdominal
pain, diarrhea, constipation, bleeding) were compared
by Fisher’s exact test. Continuous data were tested for
normality by histograms, p-p plots, and the Kolmogorov–
Smirnov test. The continuous variables before and after
treatment were compared by the Wilcoxon signed-ranks
test. Percentage of changes in liver function test and lipid
profile were calculated for each value as [(maximum value
– basal value) / basal × 100]. All comparisons were made
for a two-tailed significance level of 0.05.

3. Results
Seventy patients completed the study. Of these 70 patients,
54 were female (77.1%) and 16 were male (22.9%). The
median age of the patients was 22 (18–33) years.
Reports of gastrointestinal complaints in any period of
the treatment were 6.89 times higher in female patients (n
= 17) than male patients (n = 1) [OR: 6.89 (95% CI: 0.82–
151.09)], but this was not statistically significant according
to Fisher’s exact test (P = 0.053).
Frequency and percentage of the patients exceeding
normal values in terms of laboratory results in any period
of the treatment were as follows: alanine aminotransferase
(ALT), nine patients (12.9%); aspartate aminotransferase
(AST), four patients (5.7%); gamma-glutamyl transferase
(GGT), two patients (2.9%); triglyceride (TG), 20 patients
(28.6%); low-density lipoprotein (LDL), 46 patients
(65.7%); and total cholesterol (T-chol), 14 patients (20%).
Reference intervals are as follows: ALT, 7–35 U/L; AST,
13–41 U/L; GGT, 7–64 U/L; TG, <150 mg/dL; LDL, 0–100
mg/dL; T-chol, 0–200 mg/dL.
Comparison of the basal laboratory values with
the maximum laboratory values recorded during the
treatment revealed that there was a significant change in
each parameter of liver function tests and lipid profiles that
could be attributed to isotretinoin treatment (Wilcoxon
signed-ranks test, P < 0.05) (Table 1).
According to evaluation of the percentage of change in
laboratory values due to isotretinoin treatment, TG was the
leading parameter with the highest percentage of change
[median: 77.54 mg/dL (range: 0–478.43)] (Table 2).
There was no significant difference between the patient
group that was asymptomatic and that with at least one
symptom in terms of percentage of change of laboratory
values before and after treatment (Mann–Whitney U test,
P > 0.05).

Table 1. Comparison of the basal laboratory values with the maximum laboratory values
recorded during the treatment.
Basal

Maximum

P-value a

Median (min–max)

Median (min–max)

ALT (U/L)

15 (10–38)

19 (12–93)

0.0001

AST (U/L)

19 (11–41)

24 (16–107)

0.0001

GGT (U/L)

15.5 (7–61)

20.5 (11–77)

0.0001

TG (mg/dL)

61 (9–153)

107 (18–363)

0.0001

LDL (mg/dL)

85 (52–114)

112 (59–166)

0.0001

T-chol (mg/dL)

145 (102–200)

175 (113–243)

0.0001

Reference intervals: ALT, 7–35 U/L; AST, 13–41 U/L; GGT, 7–64 U/L; TG, <150 mg/dL;
LDL, 0–100 mg/dL; T-chol, 0–200 mg/dL.
a
Wilcoxon signed-ranks test.
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Table 2. Percentage of change in laboratory values due to
isotretinoin treatment [(maximum value – basal value) / basal
× 100].
Median

Minimum

Maximum

ALT

25.00

0

575.00

AST

28.99

0

723.08

GGT

36.60

0

285

TG

77.54

0

478.43

LDL

29.31

0

98.59

T chol

17.95

0

66.44

18
16
14
12
10
8
6
4
2
0

percentage

Figure. Percentage of gastrointestinal symptoms.

Constipation was the leading gastrointestinal
symptom among the patients. Twelve out of 70 (17.1%)
patients reported constipation during the oral isotretinoin
treatment. Three patients with complaints of constipation
reported that constipation was present before the
treatment. Nevertheless, in two of these three patients,
it was intensified by the isotretinoin treatment. Bloody
stool was the second most common symptom at 11.4%
(8/70). Nausea was the next most common symptom
at 7.1% (5/70). Two patients (2.8%) reported dyspepsia
that appeared after the isotretinoin treatment and one of
them stated that the complaint continued throughout the
isotretinoin treatment. Abdominal pain and diarrhea were
each reported in only one patient (Figure).
When we evaluated the relation between constipation
and bloody stool, four of 12 patients who complained
about constipation also had bloody stool. Furthermore,
out of the eight patients who reported bloody stool
during isotretinoin treatment, four of them also reported
constipation. According to the kappa measure of agreement
test there was a weak consistency between constipation and
bloody stool complaints that was significant statistically
(kappa: 0.305, P < 0.05).
Two patients were examined with rectosigmoidoscopy
due to the complaint of bloody stool, which appeared
during isotretinoin treatment. Constipation was the
accompanying complaint of bloody stool in both cases.
The results of the rectosigmoidoscopy examinations were
anal fissure in one of the patients and hemorrhoid with
hypertrophic anal papilla in the other.
Two patients were diagnosed with irritable bowel
syndrome (IBS); one of them was diagnosed during
isotretinoin treatment with the complaint of constipation
and the constipation ended 2 weeks after the completion
of the isotretinoin treatment. The other patient was
diagnosed with IBS with the complaints of nausea and
diarrhea 2 months after the completion of the isotretinoin
treatment, although she did not have any symptoms during
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the treatment. The patients with IBS were diagnosed using
the Manning criteria, which focus on pain relieved by
defecation, having incomplete movements, mucus in the
stool, and changes in stool consistency.
4. Discussion
The clinical use of oral isotretinoin has been associated
with reports of adverse events with various implications
for the patient. Since isotretinoin (13-cis-retinoic acid) is a
vitamin A (retinol) analog, side effects seen with this drug
are similar to the clinical findings in hypervitaminosis A
syndrome. Gastrointestinal findings of hypervitaminosis
A syndrome are anorexia, nausea, abdominal pain, and
cirrhosis. Elevated triglycerides, cholesterol, and liver
function tests are the laboratory abnormalities that can be
seen in hypervitaminosis A (5).
The liver is the principal storage site for vitamin A
(retinol) and excessive ingestion of vitamin A results in
liver disease leading to cirrhosis. Vitamin A-induced
hepatic injury apparently results from the intrinsic
toxicity of vitamin A, and the extent of the injury depends
on the dose and duration of exposure. Elevations of
aminotransferases are found in over 70% of patients with
vitamin A-induced liver injury (6).
Retinoids act by regulating the expression of the
genes that control lipoprotein metabolism at both
the transcriptional and posttranscriptional levels.
Dyslipidemia, characterized by increased TG and T-chol
levels and lowered high-density lipoprotein (HDL)
plasma concentrations, is a common side effect of retinoid
therapy (7). Although a causal relationship between
long term retinoid therapy and chronic liver toxicity has
not been demonstrated yet, hepatitis is a well-known
gastrointestinal side effect of retinoid therapy. Nonetheless,
significant hepatitis is reported to occur more commonly
with retinoids other than isotretinoin (5).
The most common systemic side effect of retinoid
therapy is an increase in the plasma TG concentrations.
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Overt hypertriglyceridemia develops in 20% of patients
who are treated with retinoids in addition to concomitant
increases of T-chol and LDL cholesterol levels and decreases
of HDL levels (7). Elevated liver function test results (and
especially the transaminases) occur in 15% of patients
during isotretinoin therapy (5). Once the treatment is
stopped, increases in liver function tests and TG values
generally return to normal within 2–4 weeks (3,8). The
results of our study correlated with the known systemic
side effects of retinoid therapy. There was a significant
elevation in liver function tests and lipid profile, the most
prominent elevation being in plasma TG concentrations.
The most common adverse reactions associated
with oral isotretinoin are the mucocutaneous effects
on the lips, eyes, mouth, and other epidermal surfaces
(3,9). Nonspecific gastrointestinal complaints of nausea,
diarrhea, and abdominal pain have been reported with
isotretinoin therapy but are uncommon (5). In our study,
abdominal pain and diarrhea were the least common
complaints, each being reported by only one patient.
Dyspepsia and nausea were more common than these but
were still not significant.
Among the possible gastrointestinal adverse effects
of isotretinoin, the most remarkable one is inflammatory
bowel disease (IBD). Since the first detailed report of an
association of oral isotretinoin therapy with IBD by Brodin
(10) in 1986, a total of 12 cases of isotretinoin-related IBD
have been reported in the English literature (11–13). Many
studies concerning the relationship between isotretinoin
and IBD have been conducted, but there is no concordance
between their results (14). Reddy et al. concluded that in a
subgroup of patients, isotretinoin might serve as a trigger
for IBD (15). Crockett et al. in their first study in 2009
mentioned that evidence was insufficient to confirm or
refute a causal association, while in their second study they
claimed that ulcerative colitis but not Crohn disease was
associated with previous isotretinoin exposure (16,17).
Unlike the former studies, Bernstein et al. concluded that
isotretinoin exposure was not associated with an increased
risk of developing IBD (18). The results of the metaanalysis
by Etminan et al. did not suggest an increase in the risk
of IBD with the use of isotretinoin (19). The outcome of
the study of Alhusayen et al. was that IBD was not related
with isotretinoin. Moreover, they stated that the risk of
IBD after topical acne medication was similar to the risk
of isotretinoin and they suggested a possible association
between IBD and acne (20). The data from an in vivo
study evaluating the effects of retinoids in mouse models

of IBD provided no evidence for a detrimental effect of
retinoid treatment on intestinal inflammation (21). In
a recent population-based case-control study by Racine
et al., isotretinoin use was not associated with increased
ulcerative colitis risk, but it was associated with decreased
Crohn disease risk (22).
Although the relationship between isotretinoin
treatment and IBD has not been clarified yet, the data from
the recent studies do not support a correlation between
isotretinoin and IBD. None of our patients were diagnosed
with IBD during isotretinoin treatment.
Anal fissure and rectal bleeding are the rarely reported
side effects of isotretinoin. The reported patients usually
complained of anal pain and rectal bleeding and some of
them declared that these symptoms were intensified by
defecation. Anal fissure is the common finding of all such
patients in examination. The possible mechanism of anal
fissure formation and rectal bleeding was explained by
tearing of the xerotic anal mucosa due to trauma, such as
forceful defecation (23–25).
In our study, bloody stool, which can be accepted as a
sign of anorectal bleeding, was the second most common
gastrointestinal symptom among our patients. Out of
eight patients two were examined by rectosigmoidoscopy
and the results were anal fissure and hemorrhoid with
hypertrophic anal papilla, respectively. Both of these
patients also had constipation symptoms. When we
evaluated the relation between constipation and bloody
stool, half of the patients who reported bloody stools
also reported constipation. There is a weak consistency
between the two complaints that is significant statistically.
We suggest that constipation may be the triggering factor
in the case of a dry and delicate mucosa, as a result of
isotretinoin therapy, for those patients who report bloody
stool.
Our study is the first to analyze both the gastrointestinal
findings and the laboratory findings of patients during
systemic isotretinoin treatment. We observed that nausea,
dyspepsia, abdominal pain, and diarrhea were the rare
gastrointestinal symptoms that can be encountered with
systemic isotretinoin therapy. Constipation and anorectal
bleeding were relatively more common symptoms and
there seems to be a relation between them. In conclusion,
both dermatologists and gastroenterologists must keep
in mind that, as well as the known laboratory findings
like hypertriglyceridemia and elevated liver function
tests, systemic isotretinoin therapy may also cause the
aforementioned clinical gastrointestinal findings.
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